Use of interferon for the treatment of chronic hepatitis C in the elderly.
Hepatitis C virus is a worldwide health care problem. It affects all age groups. Many patients have had the infection for 20-30 years before they present for therapy. With a peak incidence of disease in the 30-40 year age group, it is obvious that a large number of cases must occur in the elderly (age > 65 years). Of these, a fraction progress to cirrhosis and hepatocellular carcinoma. Interferon is the only agent approved for use in patients with chronic hepatitis C. The efficacy of interferon in younger patients is reported to be 50%. Half of these will experience a relapse within 1 year. There are few studies assessing the role of interferon used for elderly patients with chronic hepatitis C. The reported response rate to interferon in elderly patients was 60%, with 30% having a virologic/complete response. These studies demonstrate that the elderly tolerate interferon reasonably well. No significant differences have been reported between elderly and young treatment groups.
Eyigun
C P
CP
Department of Infectious Diseases, Gulhane Military Medical Academy, Ankara, Turkey.
Van Thiel
D H
DH
De Maria
N
N
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D019698:Hepatitis C, Chronic / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D015994:Incidence; D007372:Interferons / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D007372:Interferons